BCI
VRTX icon

Brinker Capital Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Brinker Capital Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447 Buy
+1
New +$466 ﹤0.01% 1948

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brinker Capital Investments's VRTX Position: Q1 2026 in Review

Brinker Capital Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, selling an estimated $135K and leaving 11,862 shares worth $5.3M. The position accounts for 0.05% of the portfolio, ranked #347.

Brinker Capital Investments first reported a position in VRTX in Q3 2015 and has held it in 30 quarters since. The position peaked at $5.51M in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Brinker Capital Investments held 11,862 shares of Vertex Pharmaceuticals worth $5.3M as of Q1 2026.
  • Brinker Capital Investments sold 289 Vertex Pharmaceuticals shares in Q1 2026, an estimated $135K.
  • Vertex Pharmaceuticals made up 0.05% of Brinker Capital Investments's portfolio in Q1 2026, its #347 holding.
  • Brinker Capital Investments first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 30 quarters since.
  • Brinker Capital Investments's Vertex Pharmaceuticals position peaked at $5.51M in Q4 2025.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.